Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Current Leases: 2014-2024

Historic Current Leases for Lineage Cell Therapeutics (LCTX) over the last 11 years, with Dec 2024 value amounting to $1.1 million.

  • Lineage Cell Therapeutics' Current Leases fell 5.54% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year decrease of 5.54%. This contributed to the annual value of $1.1 million for FY2024, which is 32.17% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Current Leases stood at $1.1 million for FY2024, which was up 32.17% from $830,000 recorded in FY2023.
  • Lineage Cell Therapeutics' 5-year Current Leases high stood at $1.1 million for FY2024, and its period low was $746,000 during FY2020.
  • For the 3-year period, Lineage Cell Therapeutics' Current Leases averaged around $947,667, with its median value being $916,000 (2022).
  • Its Current Leases has fluctuated over the past 5 years, first plummeted by 39.00% in 2020, then soared by 32.17% in 2024.
  • Lineage Cell Therapeutics' Current Leases (Yearly) stood at $746,000 in 2020, then increased by 7.37% to $801,000 in 2021, then rose by 14.36% to $916,000 in 2022, then decreased by 9.39% to $830,000 in 2023, then skyrocketed by 32.17% to $1.1 million in 2024.